Qingdao Bright Moon Seaweed Group Co., Ltd.'s pharmaceutical-grade mannitol upgrade project has been successfully put into production.
On January 16th, the completion and commissioning ceremony of the Qingdao Bright Moon Seaweed Group Co., Ltd.'s pharmaceutical-grade mannitol intelligent upgrade and transformation project was held at the group's headquarters. More than 140 people attended the event, including leaders from relevant municipal and district-level departments, industry partners, representatives from financial institutions, and outstanding employees of the group, witnessing this important moment. In his speech, Zhang Guofang, Secretary of the Party Committee and Chairman of the Board of Directors of the Group, pointed out that the official commissioning of this intelligent upgrade and transformation project is a key measure for Bright Moon Seaweed Group to actively respond to the national strategies of building a maritime power and a healthy China, and to promote the independent control of the marine biopharmaceutical industry chain. Zhang Guofang stated that in order to seize the opportunities of the "15th Five-Year Plan" for new industrialization development and to focus on the core direction of developing new quality productivity and promoting high-quality development, the group has focused on technological innovation and efficiently built an intelligent production line with internationally advanced levels. He emphasized that pharmaceutical-grade mannitol, as a core pharmaceutical raw material, has a stable supply and excellent quality that directly relates to the safety and stability of the pharmaceutical and health industry chain. This successful commissioning is not only an important breakthrough for Bright Moon Seaweed Group in the field of high-end marine biopharmaceutical manufacturing, but also a concrete manifestation of the company's commitment to serving the overall national high-quality development strategy with new quality productivity. Looking to the future, Bright Moon Seaweed Group will continue to deepen its green transformation and strengthen supply chain collaboration, contributing significantly to the construction of an independent, controllable, green, and low-carbon pharmaceutical and healthcare industry chain system. Government departments highly praised the project's efficient progress and forward-looking layout, noting that it is an important practice in cultivating new technologies and industries during the 15th Five-Year Plan period, and has demonstrative and leading significance for enhancing the competitiveness of the marine biological industry cluster in the Marine High-tech Zone and promoting the intelligent development of manufacturing. Partner representatives stated that the Group has always adhered to the concept of win-win cooperation. The release of new production capacity will bring more stable supply guarantees and higher-quality product choices to the upstream and downstream of the industry chain, effectively boosting the overall level of pharmaceutical companies in the marine biological field and injecting strong momentum into the high-quality development of the marine economy. The Bright Moon Seaweed Group's pharmaceutical-grade mannitol intelligent upgrade and transformation project deeply integrates Bright Moon's decades of core processes and technologies in the field of marine biotechnology, integrating 5G communication, industrial IoT, and cloud platform technologies to build a digital control and automated operation system covering the entire production chain. In the production process, relying on an integrated intelligent scheduling and full-process data traceability system, precise operation, stable processes, and improved efficiency are achieved, ensuring stable and reliable product quality while expanding production capacity. The mannitol series products produced all meet international pharmacopoeia standards for key indicators, fully satisfying the stringent requirements of high-end pharmaceutical preparations and health products worldwide. The company actively responds to the development orientation of "technology-driven, standard-led, and ecosystem-empowered" during the 15th Five-Year Plan period, comprehensively implementing green and sustainable concepts in its intelligent manufacturing system and systematically optimizing from the design stage. Through the integrated application of industrial big data models and AI technology, it promotes process innovation and intelligent central control collaborative management, achieving a systematic reduction in energy consumption and emissions, and effectively fulfilling the group's responsibility for the coordinated development of economic, social, and environmental benefits. This successful production launch is not only a vivid practice of the brand philosophy of "Discovering Differences, Creating Differences," but also a strategic leap for the company to seize the new development stage and reshape the industrial landscape with new quality productivity. Looking to the future, the Group will always uphold the core values of "altruism, trust, innovation, and integration," adhere to leading industrial upgrading with technological innovation, consolidate the foundation for development with intelligent manufacturing, and continuously promote the marine biological health industry towards high-end, green, and international development. With a safer and more reliable supply chain system and a more forward-looking industrial layout, the Group will serve the national strategy of building a maritime power and the global health industry.Contact Person: Yana FanMobile:+8615371019725WhatsApp/WeChat:+8615371019725E-mail:sales7@bouling-chem.com
